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Abstract
 .  .  .Secretory group II sPLA and cytosolic cPLA phospholipases A and cyclooxygenase-2 Cox-2 play a pivotal role2 2 2
in release of proinflammatory eicosanoids. Excessive activity of sPLA per se can also propagate inflammation.2
Endogenous control of the above enzymes has not been completely elucidated. We investigated the combined impact of
promoting cytokines and inhibitory peptide growth factors on the expression of mRNA of the above enzymes, on protein
 .content and extracellular release of sPLA and on PGE production in osteoblasts FRCO . The synthesis and release of2 2
sPLA were enhanced by about 20-fold by 0.5 ngrml IL-1b or by 50 ngrml of TNFa . Coaddition of both cytokines2
resulted in synergistic 150-fold increase in the release of sPLA implying the existence of two paths of induction. IL-1b2
and TNFa markedly enhanced the transcription of sPLA mRNA. Kinetic study showed that IL-1rTNF initiated sPLA2 2
release after 12 h, reaching maximum at 48 h. IL-1a was a weak stimulator of sPLA release, whereas IL-6, IL-8, IGF,2
IFN-g , growth hormone, insulin and GM-CSF were not stimulatory. Peptide growth hormones TGFb , PDGF-BB, EGF and
bFGF markedly inhibited the extracellular release of sPLA . TGFb and PDGF-BB significantly reduced the level of sPLA2 2
mRNA, thus acting upon transcription whereas EGF and bFGF were not inhibitory, acting rather upon the translational or
posttranslational steps. IL-1rTNF and growth factors had no significant effect on cPLA mRNA expression. Cox-2 mRNA2
expression was markedly enhanced by IL-1rTNF and suppressed by all growth factors tested. Cytokines enhanced the
extracellular release of PGE and further enhancement was induced by growth factors with the exception of TGFb.2
Cycloheximide abolished completely the release of sPLA and markedly reduced the release of PGE from cytokine-2 2
stimulated FRCO, regardless of whether growth factors were present or not. NS-398, a specific inhibitor of Cox-2 abolished
almost completely the release of PGE from cytokine-stimulated cells, regardless of the presence of growth factors. Thus,2
different signalling mechanisms are involved in the impact of growth factors on mRNA expression of sPLA , cPLA and2 2
Abbreviations: sPLA , secretory phospholipase A ; cPLA , cytosolic phospholipase A ; Cox, 2-cyclooxygenase-2; PGE , prosta-2 2 2 2 2
glandin E ; IL-1, interleukin 1; TNF, tumor necrosis factor; FRCO, fetal rat calvaria osteoblasts2
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Cox-2. The differences between the impact on FRCO sPLA and that reported in other cells, imply that endogenous control2
of arachidonic acid cascade is cell-specific. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The inflammatory process, regardless of its origin
is generally accompanied by de novo synthesis and
extracellular release of cytokines such as IL-1, TNF,
w xIL-6 and IL-8 1,2 . Some of these cytokines are
proinflammatory, either directly or indirectly by sub-
sequent induction of various mediators of inflamma-
w xtion 1–3 . In experimental and in clinical settings,
after the induction by IL-1, TNF, and in some in-
stances by IL-6, such mediators include proinflamma-
 .tory secretory group II phospholipase A sPLA2 2
w x4–7 . The above cytokines may also induce the
 .expression of cytosolic PLA cPLA and cyclooxy-2 2
 .genase-2 Cox-2 resulting in the synthesis of
w xeicosanoids 8–11 .
The proinflammatory role of sPLA has been well2
w xdocumented. When injected into the skin 12 , joints
w x w x13,14 , or subcutaneous air pouches 15 , sPLA 2
induces a time- and dose-dependent inflammatory
reaction. Circulating sPLA activity significantly cor-2
relates with the clinical activity of adult and juvenile
w xrheumatoid arthritis 16,17 . Circulating sPLA also2
increases markedly in systemic inflammatory re-
 .sponse syndromes SIRS , such as septic shock
w x w x w x18,19 , salicylate intoxication 20 and malaria 21 ,
correlating with hypotension, adult respiratory dis-
w xtress syndrome, coagulopathy and outcome 18,19 .
Recognition of the proinflammatory role of sPLA 2
led to an extensive search for its sources of synthesis
w x7,22–27 , and to studies of endogenous regulatory
w x w xfactors 28,29 and exogenous inhibitors 30–33 . Fe-
 .tal rat calvaria osteoblastic cells FRCO , are espe-
cially suitable for such studies since they continu-
w xously synthesize and release sPLA 6 . We reported2
that IL-1 and TNF induce the synthesis and release of
sPLA from FRCO and that cycloheximide and acti-2
w xnomycin D markedly inhibit such induction 6 .
Herein we report the modulatory role of several
cytokines and peptide growth factors in regulation of
sPLA synthesis by cytokine-stimulated FRCO. Since2
many, if not all, such modulators are coexpressed in
the inflammatory foci and are often synthesized in
w xsitu by the inflamed tissues 3,34 , it is important to
elucidate their combined impact on sPLA expres-2
sion. Furthermore, investigation of the impact of
cytokines and growth factors on the expression of
 .cytosolic PLA cPLA and cyclooxygenase-2 and2 2
on PGE release was studied and may lead to a better2
understanding of the endogenous control of arachi-
donic acid cascade and more efficient manipulation
of the inflammatory process.
2. Materials and methods
2.1. Cell cultures
 .Fetal rat calvarial osteoblasts FRCO were cul-
w xtured as described in detail 6 . Briefly, after aseptic
dissection of calvarias from 21-day fetal Wistar rats
and removal of loose adherent tissues and of perios-
teum, single-cell suspensions were prepared by diges-
tion with type I bacterial collagenase Sigma, St.
.Louis, MO . FRCO were seeded onto 35-mm plastic
dishes at 3=104 cellsrcm2 in MEM containing
 . penicillin G 100 mgrml , amphotericin B 0.3
.  .mgrml , gentamicin sulfate 50 mgrml and 15%
fetal calf serum. Media were supplemented with b-
 . glycerophosphate 10 mM and ascorbic acid 50
.mgrml . Cells were grown to confluence and pas-
saged as required. Only primary cultures and cells up
to the third passage were used in our experiments.
Cell counts and viability, tested by the trypan blue
exclusion method, were determined throughout the
duration of experiments. Cell viability at the initiation
of cultures was invariably over 95% and at the
termination of experiments over 90%. Whenever the
added agent was dissolved in HCl or acetic acid,
identical concentrations of the solvent were added to
the controls. Acetic acid added at a final concentra-
tion of 10 mM did not alter cell viability, but reduced
the final number of cells by a maximum of 15%.
Hydrochloric acid at a final concentration of 40 mM
did not influence the number or viability of cells.
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Table 1
Extracellular release of sPLA from various passages of FRCO2
a 6Passage n IL-1rTNF sPLA Ur10 cells P2
3rd 27 0 156"116
-0.0016th 6 0 4.7"5.3
3rd 27 q 15 669"8790
-0.016th 6 q 6 721"948
aIL-1b , 0.2 ngrml; TNFa , 25 ngrml.
Cytokines andror growth factors were added to
cell cultures and the cells cultured further for up to
48 h. In some experiments fetal calf serum was
withdrawn 24–48 h before addition of cytokines or
growth factors. For kinetic experiments the super-
natant samples were withdrawn at various intervals
and tested for sPLA using both enzymatic assays2
 .and Western blots vide infra . Continuous extracellu-
lar release of sPLA from unstimulated FRCO varied2
depending on the culture conditions. Withdrawal of
fetal calf serum from the culture for 48 h invariably
resulted in up to 4-fold increase in sPLA release,2
regardless of whether the cells were unstimulated or
stimulated with IL-1b andror TNFa . Cells from
early passages of FRCO released much more sPLA 2
than the later ones, primary cultures and passages
 .1–3 being the most active see Table 1 . Thus, only
early passages including the third were used in the
experiments. There was no significant difference in
the final concentration of cultured cells or their via-
bility in early or late passages. FRCO were used for
Northern blot analysis as described in Section 3.
Experiments were performed in triplicate and re-
peated at least twice.
2.2. Cytokines and growth factors
 .Recombinant human rh interleukin-1a and
 .  .
-1b IL-1a , IL-1b , tumor necrosis factor a TNF ,
rh-IFN-g , rh IGF-1, rh GM-CSF and rh PDGF-BB,
were obtained from Genzyme, Cambridge, MA. IL-6
was obtained from Peprotech., Rocky Hill, NJ. TGF-b
and rh IL-8, were purchased from R and D Systems
 .Minneapolis, MN . Rh bFGF and rh-a FGF were
obtained from Gibco, BRL, Gaithersbury, MD; rh
EGF, insulin and dexamethasone were purchased from
 .Sigma St. Louis, MO . Human growth hormone was
obtained from Eli Lilly, Indianapolis, IN.
2.3. Phospholipase A assay2
Extracellular PLA activity was assayed as de-2
w x w14 xscribed 35 . C Oleic acid-labelled Escherichia coli
 .strain K12C600 membrane phospholipids were used
as the substrate. This substrate has been characterized
with respect to phospholipid composition and distri-
bution of radiolabel. Reaction mixtures contained 10
mg bovine serum albumin, 2 mM CaCl , 2.8=1082
radiolabelled E. coli and 0.1 M Tris HCl buffer, pH
7.5 in a total volume of 1.5 ml. Reaction mixtures
were incubated at 378C for 30 min and the reaction
was terminated by filtration through a 0.45-mm Milli-
pore filter, thereby retaining unhydrolysed E. coli
w14 xmembranes, and allowing the C oleic acid bound to
the BSA carrier, released as a result of PLA hydrol-2
ysis, to pass through the filter. Assays were per-
formed in triplicate and values shown represent the
mean of three determinations with SD-5% of the
mean. Assays were performed in substrate excess and
enzyme activities were corrected for nonenzymatic
hydrolysis. One unit of PLA activity is defined as2
the hydrolysis of 56 pmol of phospholipid substrate
 .representing 1% of total E. coli phospholipid in 30
min at 378C. None of the agents listed below had a
 .direct effect on the PLA assay data not shown .2
PLA synthesized and secreted from FRCO has pre-2
viously been identified as a group II nonpancreatic
PLA . It was not recognized by anti-pancreatic PLA2 2
 .antibody data not shown and did bind to mono-
clonal antibody to rat sPLA known to recognize rat2
low molecular weight group II PLA but not group I2
w xPLA 36 .2
2.4. Western blot analysis
 .Cell culture supernatants 5–30 ml were analyzed
by SDS–polyacrylamide gel electrophoresis SDS-
.  .PAGE using 12% wrv gel at a constant voltage of
150 V. The proteins were transferred to a nitrocellu-
lose membrane in 25 mM Tris HCl, 192 mM glycine,
20% methanol, pH 8.3 buffer at 2 mArcm. The
membrane was incubated with a murine anti-rat
sPLA monoclonal antibody diluted 1:60 in TBS-T2
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buffer for 2 h. After washing, the membrane was
incubated with sheep anti-mouse IgG conjugated to
horseradish peroxidase. Detection of immunoreactive
bands was carried out using ECL Western blotting
 .detection system Amersham .
2.5. Northern blot analysis
Total RNA was extracted with Trizol from FRCO
 .Trizol Reagent, Gibco BRL, Life Technologies .
 .The RNA 10 mg was run on 1% agarose–2.2 M
formaldehyde gel and transferred onto a nylon mem-
 .brane Gene Screen Plus, Dupont, Canada by capil-
lary blotting. After immobilization of RNA at 808 for
2 h the blot was subjected to hybridization. After
hybridization the blot was washed 3–4 times with
1=SSC, 0.5% SDS solution at 508C for 2 h fol-
lowed by one wash with 0.1=SSC for 10 min at
room temperature. The probe used for hybridization
was full length cDNA. Rat sPLA , cPLA and Cox-22 2
cDNA’s and human G3PDH cDNA to monitor equal
w 32 xloading were labeled with a P dCTP using a ran-
 .dom primer labeling system Pharmacia Biotech .
The human G3PDH probe strongly hybridizes to rat
  . .G3PDH mRNA Nucleic Acids Res. 13 1985 2485 .
The blot was exposed to Kodak X-Omat AP film at
y708C with an intensifying screen for periods rang-
ing from 24 h to 6 days as required. The signals on
the autoradiographs were assessed by computing den-
sitometer Molecular Dynamics and Image Quant,
.version 4.2, Packard Canberra, CA, USA .
2.6. PGE assay2
Aliquots of supernatants from FRCO cultures were
tested in triplicate using enzyme immunoassay kit
 .PGE ELISA Assay Biotrak; Amersham, Canada .2
The assay was performed according to the manufac-
turer’s instruction. The sensitivity of the assay al-
lowed to detect quantities between 2.5–320 pgrwell
or 50–6400 pgrml. For quantities higher than the
above levels the samples were diluted in the assay
buffer.
2.7. Assay of inhibition of cyclooxygenase by NS-398
 .NS-398 Cayman Chemical, Ann Arbor, MI , spe-
cific inhibitor of Cox-2 was dissolved in DMSO
 .0.1% and added to FRCO cultures simultaneously
with cytokines andror growth factors up to the final
concentration of 2 mM. The cultures were main-
tained for up to 48 h and PGE was determined in the2
supernatants by ELISA assay.
2.8. Assay of inhibition by cycloheximide
In separate experiments FRCO, unstimulated,
stimulated with IL-1rTNF, with or without growth
factors were pretreated with cycloheximide Sigma,
.Oakville, Canada , 2 mM for 30 min. Further incuba-
tion of up to 48 h was carried out and sPLA 2
expression and PGE level estimated.2
All assays were performed in triplicate and re-
peated 2 to 6 times. Statistical analysis was per-
formed using Instat Statistics version 2.0 Graph Pad
.Software, San Diego, CA .
3. Results
There was no significant enhancement of extracel-
lular release of sPLA in the first 12 h of exposure to2
cytokines. Afterwards, rapid accumulation of the ex-
Fig. 1. Enzymatic activity of sPLA in the culture medium of2
FRCO stimulated with IL-1b or TNFa . 0sUnstimulated cells.
 .Incubation 48 h ns4 . Vertical bars mean"SD.
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tracellular sPLA was observed with no further sig-2
nificant increase after 48 h. The dose dependence of
sPLA expression is shown in Fig. 1. Maximal re-2
 .lease of sPLA =20 was achieved by 0.5 ngrml of2
 .IL-1b and by 50 ngrml of TNFa =21 . Coaddition
of IL-1b and TNFa resulted in 150-fold or more
 .increase in sPLA release Table 2 , reaching the2
maximum of 63 422"7611 Urml.
IL-1b was a much more potent stimulator of
sPLA release than IL-1a , 0.5 ngrml inducing the2
release of 1973"11 Urml and 474"21 Urml
 .respectively ns3, P-0.01 . Neither cytokine al-
tered the number of proliferating cells or viability.
IL-6 in concentrations up to 100 ngrml and IL-8,
500 ngrml had no influence on the release of sPLA 2
from unstimulated or IL-1brTNFa stimulated cells
at incubation times of up to 48 h.
The effect of growth factors on the secretion of
sPLA was tested using cytokine-stimulated FRCO2
 .Fig. 2 . TGFb markedly suppressed the expression
of sPLA concentrations as low as 4–5 ngrml in-2
hibiting the secretion of sPLA after 24 h of incuba-2
tion by 75–95%. There was no impact on unstimu-
lated cells even at concentrations of 50 ngrml. EGF
also significantly reduced the release of sPLA from2
IL-1rTNF - stimulated cells. Higher concentrations
were necessary to reduce sPLA release from un-2
stimulated cells, 50 ngrml decreasing extracellular
sPLA from 157"21 Urml to 61"14 Urml ns2
.3, P-0.005 . PDGF-BB significantly reduced the
extracellular expression of sPLA , 10 ngrml reduc-2
ing sPLA release after 24 h of incubation by 65%.2
There was no impact of PDGF-BB on unstimulated
cells. bFGF at concentration of 5 ngrml, reduced
Table 2
Release of sPLA from FRCO induced by cytokines2
a .Cytokines sPLA Urml P2
24 h 48 h
 .Controls ns18 133"22 263"25 -0.01
b .IL-1b ns6 1 076"60 1 995"170 -0.01
c .TNFa ns6 999"38 4 056"272 -0.005
d .IL-1brTNFa ns6 20 140"1685 39620"3120 -0.001
aP value, comparison of the release in 48 h vs. 24 h.
b IL-1b , 0.2 ngrml.
c TNF-a , 25 ngrnl.
d IL-1b , 0.2 ngrml; TNFa , 25 ngrml.
Fig. 2. Enzymatic activity of sPLA in the culture medium of2
FRCO stimulated with TNFarIL-1b and exposed to growth
 .  .factors ns3 . Cell viability )90%. Normal proliferation. B
 .  .  .TGFb , l PDGF-BB, ’ EGF, % bFGF. Vertical bars,
mean"SD.
sPLA release from IL-1rTNF-stimulated cells by2
up to 90%.
Western blot of extracellular sPLA protein2
showed that TGFb abolished almost completely pro-
tein secretion, followed by a less prominent effect of
PDGF-BB, EGF and bFGF. The same effect was
 .observed testing intracellular sPLA protein Fig. 3 .2
 .  .IGF 10 ngrml , aFGF up to 200 ngrml IFN-g
 . 500–1500 Urml , human growth hormone 500–
.  . 1000 ngrml , GM-CSF 50 ngrml and insulin 1
.mgrml did not alter the release of sPLA from2
unstimulated or IL-1rTNF-stimulated FRCO.
Fig. 3. Western blot of sPLA protein in FRCO incubated for 482
 .h with cytokines and growth factors. A sPLA protein in2
 .culture supernatants. B Intracellular sPLA protein isolated by2
Trizol from the samples used for estimation of sPLA mRNA.2
 .  .  . 1 Unstimulated cells. 2 IL-1b 0.2 ngrml qTNFa 25
.  .  .  .ngrml 3 IL-1rTNF with TGFb 10 ngrml 4 Il-1rTNF
 .  .  .with PDGF-BB 50 ngrml 5 Il-1rTNF with EGF 50 ngrml
 .  .6 IL-1rTNF with bFGF 10 ngrml .
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Fig. 4. Effect of growth factors on IL-1rTNF induced sPLA 2
and Cox-2 mRNA in cultured FRCO. Cells were cultured in the
presence of IL-b and TNFa and TGFb , EGF, PDGF-BB or
bFGF for 48 h. Total RNA was isolated as described in Section
2. Northern blots were prepared with 10 mg of total RNArlane.
Blots were hybridized sequentially with radiolabeled probes for
rat sPLA and Cox-2 and human G3PDH to monitor equal2
loading. Concentrations used were: IL-1b 0.2 ngrml, TNFa 25
ngrml, TGFb 10 ngrml, PDGF-BB 50 ngrml, EGF 50 ngrml,
bFGF 10 ngrml.
The effect of TGFb , PDGF-BB, bFGF and EGF
on mRNA of sPLA , cPLA and Cox-2 was tested2 2
in IL-1rTNF stimulated FRCO. TGFb and PDGF-BB
were strong suppressors of sPLA mRNA transcrip-2
 .tion Fig. 4 . Cox-2 mRNA level was strongly sup-
Fig. 5. Effect of growth factors on IL-1rTNF-induced cPLA 2
mRNA in cultured FRCO. Methods and concentrations as in
Fig. 4.
Fig. 6. Release of PGE from FRCO unstimulated and stimulated2
 .with IL-1brTNFa C and exposed to growth factors with and
 . without cycloheximide CHX . Unstimulated cells 0.73"0.18
6 .  6ngr10 cells vs. stimulated by cytokines 10.1"0.34 ngr10
.  .cells p-0.001 . Concentrations: IL-1b 0.2 ngrml, TNFa 25
ngrml, TGFb , EGF and bFGF 10 ngrml, PDGF-BB 25 ngrml.
 .Cycloheximide 2 mM ns3 in triplicate .
pressed by TGFb and bFGF and less by PDGF-BB
 .and EGF Fig. 4 . cPLA mRNA was not affected2
 .markedly by growth factors Fig. 5 .
Stimulation of FRCO with IL-1rTNF increased
the release of PGE to the medium. Increase in PGE2 2
release was found when stimulated cells were ex-
 . posed to EGF up to 17.4-fold , bFGF up to 11.3-
.  .fold or PDGF-BB up to 5.3-fold , but not to TGFb.
TGFb actually suppressed the release of PGE Fig.2
.6 . Cycloheximide, 2 mM abolished completely the
release of sPLA from IL-1rTNF stimulated FRCO,2
regardless of whether growth factors were present
 .  .n s 3 data not shown . Cycloheximide also
markedly reduced the release of PGE from IL-2
1brTNFa stimulated FRCO. Addition of bFGF, EGF
or PDGF-BB did not attenuate the suppressive activ-
 .ity of cycloheximide Fig. 6 .
NS-398, a specific inhibitor of Cox-2 abolished
 .almost completely 89–98% the release of PGE2
from FRCO stimulated with IL-1rTNF with or with-
 .out growth factors data not shown . There was no
effect of NS-398 on the release of sPLA .2
4. Discussion
 .Human nonpancreatic phospholipases A PLA2 2
w xare classified into several groups 37,38 , two of
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which—low molecular weight secretory group II
 .PLA sPLA and high molecular weight cytosolic2 2
 .PLA cPLA are the main proximal inducers of2 2
arachidonic acid cascade. To date, only sPLA was2
found to induce or promote local and systemic in-
w xflammatory processes 7 .
Because both sPLA and cPLA play an impor-2 2
tant role in arachidonic acid metabolism, the investi-
gation of endogenous modulation of these enzymes is
important. In general, the expression of PLA is2
modulated by cytokines and growth factors, yet vari-
ous cells were found to respond differently to modu-
w xlatory agents 4,6,7,24,39–42 . Not all cells, which
synthesize sPLA , respond to stimulation by cy-2
tokines with de novo synthesis and release of sPLA 2
w x43,44 . For example, using identical culture condi-
tions sPLA mRNA expression and extracellular re-2
w xlease can be induced by IL-1b in rabbit 44 but not
w xin human chondrocytes 45 . Neither cell responded
w xto TNFa , 44,45 although human articular chondro-
w xcytes possess TNFa receptors 46 . IL-1b was un-
able to induce cPLA mRNA in rabbit articular2
w xchondrocytes 43 but did induce it in human rheuma-
w xtoid synovial fibroblasts 8,11,42 , whereas there was
w xalmost no effect on sPLA gene expression 11,42 .2
In renal mesangial cells IL-1, TNF and forskolin
induced de novo synthesis and extracellular release of
w xsPLA but had no effect on cPLA 40,41,47 . Pre-2 2
treatment of these cells with TGFb or PDGF-BB
w xinhibited sPLA induction 9,47–53 .2
It was suggested that PLA secretion is regulated2
 .through the tyrosine kinase TK receptor activity and
tyrosine phosphorylation since TK inhibitors reversed
w xinhibitory activity of PDGF 52,54 . In contrast to
suppression of sPLA , growth factors can enhance2
cPLA synthesis. For example TGFb was found to2
increase activity of cPLA in guinea pig peritoneal2
w x w xmacrophages 55 and in renal mesangial cells 9 and
PDGF and EGF stimulated cPLA in Swiss 3T3 cells2
w x56 .
Such discordant results prompted us to investigate
more extensively the effect of cytokines and growth
factors on the gene expression of sPLA , cPLA and2 2
Cox-2 in FRCO, cells known to synthesize and re-
w xlease sPLA 6 . Our previous report that IL-1b and2
w xTNFa enhance extracellular release of sPLA 6 ,2
was now expanded by showing that they also in-
crease sPLA mRNA transcript in the cells. Simulta-2
neous coaddition of both cytokines resulted in marked
synergistic enhancement of sPLA release, suggest-2
ing that perhaps two different pathways transduce the
IL-1b and TNFa signals. Our finding that cyclohex-
imide abolished sPLA expression in cytokine-2
stimulated FRCO implies that pretranslational step
must be intact for the initiation of sPLA synthesis.2
Peptide growth factors, TGFb , EGF, bFGF and
PDGF-BB markedly suppressed the intra- and extra-
cellular sPLA protein in a dose-dependent manner.2
However, whereas TGFb and PDGF-BB inhibited
the expression of sPLA mRNA, EGF and bFGF did2
not. Thus, TGFb and PDGF-BB inhibited the tran-
scription of sPLA gene, whereas EGF and bFGF,2
blocked the posttranscriptional step and therefore
seemed to act upon the translational or posttrans-
lational steps.
wThe finding that, in contrast to other cells 54,56–
x58 , EGF suppressed extracellular release of sPLA 2
in FRCO is of interest. The possible reason for such
difference might be the variability in the signalling
mechanisms of the respective membrane receptors.
Signalling mechanisms of the majority of growth
factors depend upon the intrinsic receptor kinase
activity and phospholipid hydrolysis that increases
the concentration of diacylglycerol, a physiologic
w xactivator of protein kinase C 59–61 . The majority
of cell-surface receptors for growth factors possess
w xTK activity 54,62–66 . However the phosphorylation
process may also be mediated through different re-
w xceptors 64 . For example, TGF-b and EGF receptor
activity depend, at least in part, on serinerthreonine
w xkinase activity 63,67,68 . Discordant impact of
growth factors on sPLA expression in various cells2
may thus be related to the specificity of the signalling
mechanisms of the receptors.
The impact of growth factors on cPLA mRNA,2
was different from that on sPLA mRNA and showed2
minimal downregulation, whereas Cox-2 mRNA was
downregulated by all four growth factors, especially
by TGFb and bFGF. Of interest was the observation
that bFGF and EGF had a discordant impact on
mRNA of Cox-2 and sPLA , whereas TGFb and2
PDGF had a concordant effect. Discordant effects of
w xvarious growth factors were noted by others 69 . It
has recently been reported that TGFb and PDGF
inhibit sPLA synthesis by renal mesangial cells2
w xwhereas EGF increases sPLA activity 69 .2
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Since the activity of PLA ’s and Cox-2 eventually2
lead to the synthesis of eicosanoids, we studied how
cytokines and growth factors influence PGE release2
from FRCO. The impact of cytokines on PGE re-2
lease has been tested in other types of cells. Synovial
cells stimulated with IL-1 synthesized and released
w xPGE 8 . Simultaneous increase in cPLA and Cox-22 2
mRNA was found, whereas increase in sPLA mRNA2
w xwas of smaller magnitude 8 . It was therefore con-
cluded that the latter did not play a significant role in
w xPGE synthesis 8 . In another study stimulation of2
synovial fibroblasts with IL-1b induced marked re-
lease of PGE without concomitant increase in sPLA2 2
activity or protein but with some increase in cPLA 2
w x w x11 and in Cox-2 transcript 42 . No specific in-
hibitors were used in the above studies, thus no final
elucidation of the role of individual enzymes was
possible.
Study of rabbit articular chondrocytes showed syn-
w xergistic induction of PGE by IL-1b and TNFa 70 .2
PGE synthesis was linked to Cox-2 expression but2
w xnot to sPLA or cPLA activity 70 . Because the2 2
expression of PLA enzymes in arachidonic acid2
cascade is a kinetic process, steady state estimation of
PLA ’s mRNA reported in the above study does not2
allow definite conclusions regarding the induction of
PGE release.2
We reported previously that FRCO stimulated with
w xIL-1 released more PGE than controls 22 . In the2
present study we have shown that stimulation with
IL-1brTNFa markedly increases the release of
PGE , and that growth factors with the exception of2
TGFb , increase further the expression of PGE . These2
results confirm those of others who showed that
bFGF induces PGE release from neonatal mouse2
calvaria osteoblasts and MC3T3-E1 cells. Because
marked induction of mRNA and protein of Cox-2
was observed and because the addition of exogenous
arachidonic acid was not necessary to enhance PGE2
synthesis, it was concluded that the induction occurs
w xat the level of transcription 71 . bFGF was also
found to induce the release of PGE from rheumatoid2
synovial cells, whereas PDGF was inactive. Although
increased intracellular PLA activity was noted, it2
was suggested that bFGF acts solely through the
w xactivation of Cox-2 72 .
Our study has shown that the induction of PGE2
expression by growth factors occurs simultaneously
with suppression of sPLA and Cox-2 mRNA and2
insignificant change in cPLA mRNA. Yet, NS-398,2
specific inhibitor of Cox-2, was sufficient to abolish
almost completely the release of PGE from the2
cells. The interpretation of these results may be
twofold. The lack of downregulation of PGE by2
growth factors may mean that arachidonic acid as the
precursor of PGE is mobilized by cPLA rather2 2
than sPLA . Furthermore, our studies examined the2
level of Cox-2 message and not Cox-2 enzymatic
activity. The synthesis of PGE may depend on the2
presence of active Cox-2 enzyme and the message
may not be rate-limiting.
Therefore when the cells which synthesize sPLA ,2
cPLA and Cox-2 are exposed simultaneously to2
both inhibitors and enhancers, they respond differ-
ently to such factors. The extent of the synthesis and
activity of the above enzymes and extracellular re-
lease of sPLA probably depend on the impact of2
 .predominating agent s . One of the means to modu-
late the synthesis of proinflammatory enzymes would
be to learn how to suppress the activity of factors
which upregulate their expression.
Acknowledgements
This work was supported in part by a research
grant from the Medical Research Council of Canada.
The authors acknowledge the excellent technical help
of Mr. M. Wloch.
References
w x1 S.W. Evans, J.T. Whicher, Immunol. Med. Series, in: J.T.
 .Whicher, S.W. Evans Eds. , Vol. 18, Kluwer. Acad. Publ.,
London, 1992, pp. 1–15.
w x2 S. Akira, T. Hirano, T. Taga, T. Kishimoto, FASEB J. 4
 .1990 2860–2867.
w x  .3 W.P. Arend, J.-M. Dayer, Arthritis Rheum. 33 1990 305–
315.
w x4 C. Schalkwijk, J. Pfeilschifter, F. Marki, H. van den Bosch,
 .Biochem. Biophys. Res. Commun. 174 1991 268–275.
w x5 M. Goppelt-Struebe, W. Rehfeldt, Biochim. Biophys. Acta
 .1127 1992 163–167.
( )W. Pruzanski et al.rBiochimica et Biophysica Acta 1403 1998 47–56 55
w x6 P. Vadas, W. Pruzanski, E. Stefanski, L.G. Ellies, J.E.
 .Aubin, A. Sos, A. Melcher, Immunol. Lett. 28 1991
187–194.
w x7 P. Vadas, J. Browning, J. Edelson, W. Pruzanski, J. Lipid
 .Mediators 8 1993 1–30.
w x8 J. Angel, F. Berenbaum, C. Le Denmat, T. Nevalainen, J.
 .Masliah, C. Fournier, Eur. J. Biochem. 226 1994 125–131.
w x9 C.G. Schalkwijk, E. de Vet, J. Pfeilschifter, H. van den
 .Bosch, Eur. J. Biochem. 210 1992 169–176.
w x10 C.G. Schalkwijk, M. Vervoordeldonk, J. Pfeilschifter, H.
 .van den Bosch, FEBS Lett. 333 1993 339–343.
w x11 K.I. Hulkower, W.C. Hope, T. Chen, C.M. Anderson, J.W.
Coffey, D.W. Morgan, Biochem. Biophys. Res. Commun.
 .184 1992 712–718.
w x12 W. Pruzanski, P. Vadas, V. Fornasier, J. Invest. Dermatol.
 .86 1986 380–383.
w x13 P. Vadas, W. Pruzanski, J. Kim, V. Fornasier, Am. J.
 .Pathol. 134 1989 807–811.
w x14 J.S. Bomalaski, P. Lawton, J. Browning, J. Immunol. 146
 .1991 3904–3910.
w x15 G. Cirino, C. Cicala, L. Sorrentino, F.M. Maiello, J.L.
 .Browning, J. Rheumatol. 21 1994 824–829.
w x16 M. Koo Seen Lin, V. Farewell, P. Vadas, A.A.M. Bookman,
 .E.C. Keystone, W. Pruzanski, J. Rheumatol. 23 1996
1162–1166.
w x17 W. Pruzanski, K. Albin-Cook, R. Laxer, J. MacMillan, E.
 .Stefanski, P. Vadas, E. Silverman, J. Rheumatol. 21 1994
1951–1954.
w x18 P. Vadas, W. Pruzanski, E. Stefanski, B. Sternby, R. Mus-
tard, J. Bohnen, I. Fraser, V. Farewell, C. Bombardier, Crit.
 .Care Med. 16 1988 1–7.
w x19 P. Vadas, K. Scott, G. Smith, I. Rajkovic, E. Stefanski, B.D.
 .Schouten, R. Singh, W. Pruzanski, Life Sci. 50 1992
807–811.
w x20 P. Vadas, B. Schouten, E. Stefanski, K. Scott, W. Pruzanski,
 .Crit. Care Med. 21 1993 1087–1091.
w x21 P. Vadas, J. Keystone, E. Stefanski, K. Scott, W. Pruzanski,
 .Infect. Immun. 60 1992 3928–3931.
w x22 L.G. Ellies, J.N.M. Heersche, P. Vadas, W. Pruzanski, E.
 .Stefanski, J.E. Aubin, J. Bone Miner. Res. 6 1991 843–850.
w x23 W. Pruzanski, E. Bogoch, E. Stefanski, M. Wloch, P.
 .Vadas, J. Rheumatol. 17 1990 1386–1391.
w x  .24 S. Oka, H. Arita, J. Biol. Chem. 266 1991 9956–9960.
w x25 T. Nakano, O. Ohara, H. Teraoka, H. Arita, FEBS Lett. 261
 .1990 171–174.
w x26 R.M. Crowl, T.J. Stoller, R.R. Conroy, C.R. Stoner, J. Biol.
 .Chem. 266 1991 2647–2651.
w x27 S.C. Gilman, J. Chang, P.R. Zeigler, J. Uhl, E. Mochan,
 .Arthritis Rheum. 31 1988 126–130.
w x  .28 R.F. Flower, Br. J. Pharmacol. 94 1988 987–1015.
w x29 Y. Suwa, I. Kudo, A. Imaizumi, M. Okada, T. Kimimura,
Y. Suzuki, H.W. Chang, S. Hara, K. Inoue, Proc. Natl.
 .Acad. Sci. U.S.A. 87 1990 2395–2399.
w x30 H.G. Beaton, C. Bennion, S. Connolly, A.R. Cook, N.P.
Gensmantel, C. Hallam, K. Hardy, B. Hitchin, C.G. Jack-
 .son, D.H. Robinson, J. Med. Chem. 37 1994 557–559.
w x31 R.A. LeMahieu, M. Carson, R.J. Han, V.S. Madison, W.C.
Hope, T. Chen, D.W. Morgan, H.S. Hendrickson, J. Med.
 .Chem. 36 1993 3029–3031.
w x32 A. Miyake, H. Yamamoto, E. Kubota, K. Hamaguchi, A.
Kouda, K. Honda, H. Kawashima, Br. J. Pharmacol. 110
 .1993 447–453.
w x33 K. Tanaka, S. Matsutani, K. Matsumoto, T. Yoshida, J.
 .Antibiotics 45 1993 1071–1078.
w x34 M. Feldmann, F.M. Brennan, R.O. Williams, A.P. Cope,
D.L. Gibbons, P.D. Katsikis, R.N. Maini, Prog. Growth
 .Factor Res. 4 1992 247–255.
w x35 E. Stefanski, W. Pruzanski, B. Sternby, P. Vadas, J.
 .Biochem. 100 1986 1297–1303.
w x36 J.G. de Jong, H. Amesz, A.J. Aarsman, H.B. Lenting, H.
 .van den Bosch, Eur. J. Biochem. 164 1987 129–135.
w x  .37 E.A. Dennis, Trends Biol. Sci. 22 1997 1–2.
w x38 H. van de Bosch, A.J. Aarsman, R.H. van Schaik, C.G.
Schalkwijk, F.W. Neijs, A. Sturk, Biochem. Soc. Trans. 18
 .1990 781–785.
w x39 J. Pfeilschifter, C. Schalkwijk, V.A. Briner, H. van den
 .Bosch, J. Clin. Invest. 92 1993 2516–2523.
w x40 J. Pfeilschifter, W. Pignat, K. Vosbeck, F. Marki, Biochem.
 .Biophys. Res. Commun. 159 1989 385–394.
w x41 C. Schalkwijk, J. Pfeilschifter, F. Marki, Biochem. Biophys.
 .Res. Commun. 174 1991 268–275.
w x42 K.I. Hulkower, S.J. Wertheimer, W. Levin, J.W. Coffey,
C.M. Anderson, T. Chen, D.L. DeWitt, R.M. Crowl, W.C.
 .Hope, D.W. Morgan, Arthritis Rheum. 37 1994 653–661.
w x43 F. Berenbaum, G. Thomas, S. Poiraudeau, G. Bereziat, M.T.
 .Corvol, J. Masliah, FEBS Lett. 340 1994 51–55.
w x44 B. Lyons-Giordano, M.A. Pratta, W. Galbraith, G.L. Davis,
 .E.C. Arner, Exp. Cell Res. 206 1993 58–62.
w x45 W. Pruzanski, E. Bogoch, A. Katz, M. Wloch, E. Stefanski,
 .B. Grouix, G. Sakotic, P. Vadas, J. Rheum. 22 1995
2114–2119.
w x46 S. Alsalameh, B. Mattka, H.M. Lorenz, B. Manger, K.
Pfizenmaier, M. Gorell, J.R. Kalden, Athritis Rheum. 39
 .1996 S36, Supplement.
w x47 H. van den Bosch, C. Schalkwijk, J. Pfeilschifter, F. Marki,
 .Adv. Exp. Med. Biol. 318 1992 1–10.
w x48 C. Schalkwijk, M. Vervoordeldonk, J. Pfeilschifter, F. Marki,
H. van den Bosch, Biochem. Biophys. Res. Commun. 180
 .1991 46–52.
w x49 H. van den Bosch, in: Esterases, lipases and phospholipases:
from structure to clinical significance, NATO Advanced
Research Workshop, 1993, p. 26.
w x50 C. Schalkwijk, J. Pfeilschifter, F. Marki, H. van den Bosch,
 .J. Biol. Chem. 267 1992 8846–8851.
w x51 M.J. Vervoordeldonk, C.G. Schalkwijk, B.S. Vishwanath,
A.J. Aarsman, H. van den Bosch, Biochim. Biophys. Acta
 .1224 1994 541–550.
w x52 H. Muhl, T. Geiger, W. Pignat, F. Marki, H. van den Bosch,
 .K. Vosbeck, J. Pfeilschifter, FEBS Lett. 291 1991 249–
252.
w x53 J. Pfeilschifter, W. Pignat, J. Leighton, F. Marki, K. Vos-
 .beck, S. Alkan, Biochem. J. 270 1990 269–271.
w x54 H.J. Goldberg, M.M. Viegas, B.L. Margolis, J. Schlessinger,
 .K.L. Skorecki, Biochem. J. 267 1990 461–465.
( )W. Pruzanski et al.rBiochimica et Biophysica Acta 1403 1998 47–5656
w x55 M. Bolognese, M. McCord, L.A. Marshall, Biochim. Bio-
 .phys. Acta 1256 1995 201–209.
w x  .56 J. Domin, E. Rozengurt, J. Biol. Chem. 268 1993 8927–
8934.
w x57 N. Hack, B. Margolis, A. Ullrich, J. Schlessinger, K. Sko-
 .recki, JASN 1 1990 455.
w x58 J.V. Bonventre, J.H. Gronich, R.A. Nemenoff, J. Biol.
 .Chem. 265 1990 4934–4938.
w x59 R.M. Johnson, M.A. Napier, M.J. Cronin, K.L. King, En-
 .docrinology 127 1990 2099–2103.
w x60 A.J.R. Habenicht, J.A. Glomset, W.C. King, C. Nist, C.D.
 .Mitchell, R. Ross, J. Biol. Chem. 256 1981 12329–12335.
w x61 L.J. Pike, D.F. Bowen-Pope, R. Ross, E.G. Krebs, J. Biol.
 .Chem. 258 1983 9383–9390.
w x  .62 S.J. Decker, J. Biochem. 268 1993 9176–9179.
w x  .63 T. Taga, T. Kishimoto, FASEB J. 7 1993 3387–3396.
w x64 T. Kadowaki, S. Koyasu, E. Nishida, K. Tobe, T. Izumi, F.
Takaku, H. Sakai, I. Yahara, M. Kasuga, J. Biochem. 262
 .1987 7342–7350.
w x  .65 F.C. Nielsen, Growth Factor Res. 4 1992 257–290.
w x66 W.S. Chen, C.S. Lazar, M. Poenie, R.Y. Tsien, G.N. Gill,
 .M.G. Rosenfeld, Nature 328 1987 820–823.
w x67 H.Y. Lin, X.-F. Wang, E. Ng-Eaton, R.A. Weinberg, H.F.
 .Lodish, Cell 68 1992 775–785.
w x68 C.G. Schalkwijk, M. Spaargaren, L.H.K. Defize, A.J.
Verkleij, H. van den Bosch, J. Boonstra, Eur. J. Biochem.
 .231 1995 593–601.
w x69 H. van den Bosch, M.J. Vervoordeldonk, C.G. Schalkwijk,
J. Pfeilschifter, Phospholipase A . Basic and clinical aspects2
 .in inflammatory diseases, Prog. Surg. 24 1997 23–30.
w x70 F. Berenbaum, C. Jacques, G. Thomas, M.T. Corvol, G.
 .Bereziat, J. Masliah, Exp. Cell. Res. 222 1996 379–384.
w x71 H. Kawaguschi, C.C. Pilbeam, G. Gronowicz, C. Abreu,
B.S. Fletcher, H.R. Herschman, L.G. Raisz, M.M. Hurley, J.
 .Clin. Invest. 96 1995 923–930.
w x72 D.H. Goddard, S.L. Grossman, R. Newton, M.A. Clark, J.S.
 .Bomalaski, Cytokine 4 1992 377–384.
